Annual report pursuant to Section 13 and 15(d)

Condensed Consolidated Statement of Changes in Stockholders' Equity

v3.21.1
Condensed Consolidated Statement of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Series A Preferred Stock [Member]
Common Stock [Member]
Shares Issuable [Member]
Treasury Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Deficit [Member]
Non-Controlling Interests [Member]
Total
Balance at Dec. 31, 2018 $ 1 $ 58 $ 659   $ 397,408 $ (396,274) $ 17,891 $ 19,743
Balance (in shares) at Dec. 31, 2018 1,000,000 57,845,447            
Stock-based compensation expense         13,188     13,188
Settlement of restricted stock units into common stock   $ 2     (2)      
Settlement of restricted stock units into common stock (in shares)   1,905,367            
Issuance of common stock under ESPP         123     123
Issuance of common stock under ESPP (in shares)   98,007            
Issuance of common stock for at-the-market offering, net   $ 12     20,235     20,247
Issuance of common stock for at-the-market offering, net (in shares)   11,798,468            
Preferred A dividends declared and paid         (2,559)     (2,559)
Issuance of Series A preferred stock for cash, net         5,307     5,307
Issuance of Series A preferred stock for cash, net (in shares) 301,875              
Partner company's offering, net         78,607     78,607
Partner company's at-the-market offering, net         29,785     29,785
Issuance of partner company's common shares for license expenses     (164)   164      
Issuance of partner company's common shares for research and development expenses         90     90
Issuance of Series A preferred stock for at-the-market offering, net         788     788
Issuance of Series A preferred stock for at-the-market offering, net (in shares) 39,292              
Issuance of partner company warrants in conjunction with Horizon Notes         888     888
Common shares issuable for 2017 Subordinated Note Financing interest expense     500         500
Common shares issued for 2017 Subordinated Note Financing interest expense   $ 2 (495)   1,967     1,474
Common shares issued for 2017 Subordinated Note Financing interest expense (in shares)   1,637,936            
Common shares issuable for Opus interest expense     281         281
Common shares issued for Opus interest expense     (281)   662     381
Common shares issued for Opus interest expense (in shares)   345,375            
Common shares issued for Opus debt         500     500
Common shares issued for Opus debt (in shares)   396,825            
Non-controlling interest in subsidiaries         (85,277)   85,277  
Deconsolidation of Caelum non-controlling interest             4,849 4,849
Net loss attributable to non-controlling interest             (61,700) (61,700)
Net loss attributable to common stockholders           (39,960)   (39,960)
Balance at Dec. 31, 2019 $ 1 $ 74 500   461,874 (436,234) 46,317 72,532
Balance (in shares) at Dec. 31, 2019 1,341,167 74,027,425            
Stock-based compensation expense         13,451     13,451
Issuance of common stock related to equity plans   $ 2     16     18
Issuance of common stock related to equity plans (in shares)   2,335,808            
Issuance of common stock under ESPP         253     253
Issuance of common stock under ESPP (in shares)   122,786            
Issuance of common stock for at-the-market offering, net   $ 18     45,809     45,827
Issuance of common stock for at-the-market offering, net (in shares)   17,409,257            
Preferred A dividends declared and paid         (6,515)     (6,515)
Repurchase of Series A preferred stock, net       $ (70) (2)     (72)
Repurchase of Series A preferred stock (in shares) (5,000)              
Retirement of Series A preferred stock       $ 70 (70)      
Issuance of Series A preferred stock for cash, net $ 2       35,541     35,543
Issuance of Series A preferred stock for cash, net (in shares) 2,090,971              
Partner company's offering, net         53,749     53,749
Partner company's at-the-market offering, net         70,988     70,988
Partner company's preferred stock offering, net         7,074     7,074
Issuance of common stock under partner company's ESPP         349     349
Partner company's dividends declared and paid         (237)     (237)
Issuance of partner company's common shares for research and development expenses         46     46
Partner company's exercise of warrants for cash         13     13
Partner company's exercise of options for cash         13     13
Reclass partner company's warrants from liability to equity         1,216     1,216
Issuance of partner company warrants in conjunction with Horizon Notes               0
Common shares issuable for 2017 Subordinated Note Financing interest expense   $ 1 $ (500)   1,816     1,317
Common shares issued for 2017 Subordinated Note Financing interest expense (in shares)   982,216            
Issuance of warrants in conjunction with Oaktree Note         4,419     4,419
Non-controlling interest in subsidiaries         (106,803)   106,803  
Net loss attributable to non-controlling interest             (56,459) (56,459)
Net loss attributable to common stockholders           (46,526)   (46,526)
Balance at Dec. 31, 2020 $ 3 $ 95     $ 583,000 $ (482,760) $ 96,661 $ 196,999
Balance (in shares) at Dec. 31, 2020 3,427,138 94,877,492